The semi-invariant natural killer (NK) T-cell receptor (NKTcr) recognises structurally diverse glycolipid antigens presented by the monomorphic CD1d molecule. While the a-chain of the NKTcr is invariant, the b-chain is more diverse, but how this diversity enables the NKTcr to recognise diverse antigens, such as an a-linked monosaccharide (a-galactosylceramide and a-galactosyldiacylglycerol) and the b-linked trisaccharide (isoglobotriaosylceramide), is unclear. We demonstrate here that NKTcrs, which varied in their b-chain usage, recognised diverse glycolipid antigens with a similar binding mode on CD1d. Nevertheless, the NKTcrs recognised distinct epitopic sites within these antigens, including a-galactosylceramide, the structurally similar a-galactosyldiacylglycerol and the very distinct isoglobotriaosylceramide. We also show that the relative roles of the CDR loops within the NKTcr b-chain varied as a function of the antigen. Thus, while NKTcrs characteristically use a conserved docking mode, the NKTcr b-chain allows these cells to recognise unique aspects of structurally diverse CD1d-restricted ligands.
Introduction
The antigen receptor of ab T cells faces a daunting recognition problem because each T-cell receptor (TCR) interfaces multiple ligands during its lifetime and yet maintains specificity. They recognise self-ligand (peptide or lipid) in the context of a self-antigen-presenting molecule (major histocompatibility complex (MHC) class I, class II or CD1) in the thymus; foreign ligand in the context of a self-MHC/CD1 molecule in the periphery; and in some cases, non-self-ligands in the context of non-self-MHC molecules. This recognition conundrum is much more daunting for the semi-invariant natural killer (NK) T-cell receptor (NKTcr) because its recognition landscape is predominantly germline-encoded and, hence, highly conserved Scott-Browne et al, 2007; Wun et al, 2008) , while the antigenic landscapes of CD1d-lipid complexes are highly diverse (Koch et al, 2005; Zajonc et al, 2005 Zajonc et al, , 2008 Kinjo et al, 2006) . Understanding how NKT cells see extremely diverse lipid antigens is important because this innate T lymphocyte regulates early immune responses to pathogens and tumours, and is a target for immunotherapy against some autoimmune diseases (Van Kaer, 2005) .
The TCR a and b-chains each comprise variable (V) and constant (C) domains, in which the V domains contain the complementarity determining region-1 (CDR1), CDR2 and CDR3, that interact with the peptide-laden MHC (pMHC) molecules. While variations within V-gene segments confer diversity to CDR1 and CDR2, imprecise joining and nontemplated nucleotide additions during V(D)J recombination generate the much more diverse CDR3 (Rudolph et al, 2006) . TCR specificity is not limited to peptidic antigens. NKT cells express a semi-invariant TCR that recognises lipid-based antigens presented by the monomorphic CD1d molecule. The NKTcr is made up of an invariant TCR a-chain, which is generated by TRAV11*02 (mouse and rat Va14) to TRAJ18 (Ja18) or orthologous TRAV10 (human Va24) to TRAJ18 rearrangement. Despite the stochastic nature of V(D)J recombination, stringent intrathymic selection steps permit only one CDR3a for NKT cells. Thus, NKT cells express a completely invariant TCR a-chain that is highly conserved across species (Koseki et al, 1990; Porcelli et al, 1993; Dellabona et al, 1994; Lantz and Bendelac, 1994) . In contrast, CDR3b of TRBV13-2*01 (mouse Vb8.2) and the orthologous TRBV25-1 (human Vb11), which pair with the invariant Va14 and Va24 a-chains, respectively, are highly diverse (Porcelli et al, 1993; Lantz and Bendelac, 1994) . So too are the CDR3b of TRBV29*02 (Vb7) and TRBV1 (Vb2) b-chains, which also pair with Va14 and Va24 a-chains in mice (Lantz and Bendelac, 1994; Capone et al, 2003) . Thus, NKT cells have an invariant TCR a-chain, but maintain some diversity in their TCR b-chain, which is why they are referred to as semi-invariant.
The NKTcr binds structurally diverse CD1d-restricted ligands that range from a-linked monohexosylceramides such as the prototypic NKT-cell antigen a-galactosylceramide (aGalCer; Kawano et al, 1997; Burdin et al, 1998) and the closely related a-galacturonosylceramide (aGalACer; Sphingomonas spp.; Kinjo et al, 2005; Mattner et al, 2005; Sriram et al, 2005) ; a-galactosyldiacylglycerol (aGalDAG; Borrelia burgdorferi) (Kinjo et al, 2006) , to the trihexosylceramide isoglobotriaosylceramide (iGb3) Zhou et al, 2004) . Despite this apparent diversity, most mammalian glycolipids are not recognised by the NKTcr, including lactosylceramide (LacCer), globotriaosylceramide (Gb3; a1,4Gal-LacCer), which is closely related to iGb3 (a1,3Gal-LacCer), monosialylganglioside GM1 (a2,3sialyl-LacCer) or isoglobotetraosylceramide (iGb4) (Zhou et al, 2004) . A small subset of NKTcrs also recognise phosphatidylethanolamine (Rauch et al, 2003) , phosphatidylinositol (Gumperz et al, 2000) , b-galactosylceramide (Ortaldo et al, 2004; Parekh et al, 2004) , the disialylganglioside GD3 (Wu et al, 2003) and microbial phosphatidylinositol-mannoside (PIM 4 ; Mycobacterium tuberculosis (Fischer et al, 2004) . Crystal structures of several CD1d-antigen complexes showed that these lipids bind to CD1d through their long-chain base (LCB) and/or fatty acyl chain(s) so that the polar head groups protrude out of the CD1d antigen-binding site (ABS). Furthermore, the disposition of the head group depends on the unique pattern of hydrogenbond network formed by residues of CD1d a1 and a2-helices with the polar aspects of the bound ligand (Giabbai et al, 2005; Koch et al, 2005; Zajonc et al, 2005 . Thus, the a-linked galactose of aGalCer lies just above the entrance, flat and parallel to the plain of CD1d's ABS (Koch et al, 2005; Zajonc et al, 2005) . In striking contrast, the b-anomeric linkage of the first sugar orients the glycan a1,3Gal-b1, 4Gal-b1,1 0 Glc of iGb3 perpendicular to the ABS (Zajonc et al, 2008) . How the semi-invariant NKTcr recognises multiple diverse ligands in the context of CD1d remains an enigma.
A major advance in understanding how the NKTcr recognises its cognate antigen came from the crystal structure of the human NKTcr/CD1d-aGalCer co-complex . It showed that the Va24 NKTcr interfaces CD1d-aGalCer in an unusual parallel docking mode by engaging germline-encoded CDR1a, CDR3a and CDR2b residues above the F' pocket Wun et al, 2008) . Further, alanine-scanning mutagenesis of mouse and human NKTcrs revealed that they interact with CD1d-aGalCer similarly by using germline-encoded hotspots within CDR1a, CDR3a and CDR2b (Scott-Browne et al, 2007; Wun et al, 2008) . One of these studies also revealed that the Va14 NKTcr bound to CD1d-aGalCer and the very different CD1d-iGb3 landscapes in a conserved manner, using similar germline-encoded hotspots (Scott-Browne et al, 2007). The NKTcr showed very little conformational change upon ligation (Gadola et al, 2006; Kjer-Nielsen et al, 2006; Borg et al, 2007; Zajonc et al, 2008) , consistent with a 'lock and key' recognition model where neither temperature nor ionic strength affected the CD1d-aGalCer interaction (Cantu et al, 2003) . These findings suggest that the NKTcr acts like a patternrecognition receptor and also explain why the NKTcr ligand recognition is CD1d-restricted. Yet, these studies provide little insight into ligand specificity and the molecular features of the diverse epitopes recognised, and do not explain the basis for distinct TCR b-chain usage for antigen recognition by the NKTcr.
As an approach to understand the role of b-chain in CD1d-restricted antigen recognition, we probed a panel of NKT-cellderived hybridomas that express different TCR b-chains, as well as a panel of NKTcr point mutants that have altered CDR, with a variety of CD1d-restricted glycolipid ligands and variants with modifications of their sugar moieties. From the recognition patterns that emerged, we concluded that the NKTcr was highly adaptable, depending on the b-chain used, to recognise unique aspects of structurally diverse ligands within a conserved binding footprint on CD1d molecules.
Results

TCR b-chain usage dictates diverse glycolipid antigen recognition by the NKTcr
Unlike the CDR3a of the NKTcr, the CDR3b is highly diverse, both in length and primary structure (e.g., Supplementary  Table S1 ). Additionally, CDR1b and CDR2b of distinct b-chains differ from each other. Because mouse NKTcr use multiple different b-chains (Vb8.2, Vb7 and Vb2, as well as Vb14 and Vb6; Porcelli et al, 1993; Lantz and Bendelac, 1994) , we hypothesised that differences within CDR1b, CDR2b and CDR3b account for the ability of NKTcr to recognise diverse lipid antigens. Using a panel of NKT hybridomas expressing identical Va14 a-chain paired with four commonly used b-chains (Vb8.2, Vb14, Vb7 and Vb6; Lantz and Bendelac, 1994; Gui et al, 2001) , we determined whether TCR b-chain usage influences recognition of diverse glycolipid ligands (Supplementary Figure S1A) . Note that Vb8.2, Vb14, Vb7 and Vb6 have diverse CDR1b, but partly conserved, CDR2b sequences (e.g., Y46 and/or Y48 residues that were critical for interaction with the a1-helix of CD1d; Borg et al, 2007; Scott-Browne et al, 2007; Wun et al, 2008; Mallevaey et al, 2009; Pellicci et al, 2009) . Additionally, the NKT hybridomas expressed diverse CDR3b regions in association with the same Vb-region and, hence, the same CDR1b and CDR2b (Supplementary Table S1 ).
Bone marrow-derived dendritic cells (BMDCs) pulsed with aGalCer, iGb3 or aGalDAG were co-cultivated with the above NKT hybridoma panel and IL-2 secretion was assessed as a measure of activation. The data showed that the Vb8.2 þ , Vb14 þ and Vb7 þ hybridomas recognised aGalCer whereas the Vb6 þ hybridoma did not ( Figure 1A ), despite the fact that these hybridomas showed comparable response to antigen-independent stimulation through CD3e ( Figure 1D ). These data are consistent with previous reports, which demonstrated that several NKTcr b-chains are permissive to aGalCer recognition ). The Vb8.2Jb2.6 þ hybridoma was autoreactive (i.e., in the absence of exogenously added lipid) to BMDCs and was included as a positive control for the assay ( Figure 1C) .
Compared with the aGalCer recognition pattern, the recognition of iGb3 and aGalDAG by this hybridoma panel was clearly distinct (Figure 1 ). With the exception of the Vb8.2Jb2.2 þ hybridoma, most Vb8.2 þ NKT hybridomas recognised iGb3 ( Figure 1B ). While the Vb7 þ hybridoma also recognised iGb3, the Vb14 þ and Vb6 þ hybridomas did not ( Figure 1B ). Note that a titration experiment showed that the hybridoma panel required a minimum of 10 mg of iGb3 and 20 mg of aGalDAG for recognition (data not shown). Therefore, because micelle formation and bioavailability influence lipid antigen presentation at higher concentrations, the functional avidity of the different Vb-expressing NKTcrs for iGb3 and aGalDAG could not be determined.
As the aforementioned experiment used phytosphingosinecontaining iGb3 (Supplementary Figure S1A) , we determined whether the chemical make-up of the LCB influenced the recognition pattern. iGb3 made up of sphingosine-, sphinganine (4,5-dihydro)-and 4,5-dibromosphinganine-containing LCB were recognised just as well as phytosphingosine-based iGb3 (data not shown), suggesting that the chemical composition of the sphingoid backbone had very little influence on iGb3 recognition. Finally, all Vb8.2 þ , the Vb7 þ and only the Vb14Jb1.2i þ hybridomas recognised aGalDAG ( Figure 1C ), whereas the remaining three Vb14 þ and the Vb6 þ hybridomas were unresponsive to this antigen ( Figure 1C ).
The varied antigen-recognition pattern could have resulted from variation in TCR expression and differences in the activation threshold of the different NKT hybridomas. Therefore, we determined the IL-2 response of each NKT hybridoma to antigen-independent stimulation using anti-CD3e monoclonal antibody (mAb). All hybridomas responded similarly to this stimulation ( Figure 1D ). This result suggests that the recognition pattern of NKT hybridomas was intrinsic to the NKTcr and not due to variation in TCR expression levels or activation threshold. Taken together, the above data suggest that CDR3b together with CDR1b and CDR2b dictate NKTcr's ability to recognise structurally diverse ligands. Alternatively, although less likely, other cell-surface molecules differentially expressed by the hybridomas could result in the observed differences in responses.
Vb usage impacts the recognition of 3
0 and 4 0 aGalCer analogues To gain insight into how the NKTcr recognises aGalCer, we used aGalCer analogues, which contain modifications at the 3 0 -and 4 0 -hydroxyls of galactose (Supplementary Figure S1B) . Note that the aGalCer analogues contained C 8 acyl chain, which does not alter the conformation of CD1d upon binding Figure S2 ) ) yet their deoxy forms were reported not to affect recognition (Wun et al, 2008) . Therefore, we determined whether chemical modifications at the 3 0 (-amino, -azido and -N-acetyl) and 4 0 (-O-methyl, -O-ethanol and -N-acetyl) of galactose are recognised by NKTcr, and whether Vb usage influences this recognition using the approach described above. Replacement of the 3 0 -hydroxyl with an -amino, -azido or -N-acetyl group prevented recognition by the NKT hybridoma panel regardless of the NKTcr's b-chain composition ( Figure 2A ). Therefore, although the 3 0 -hydroxyl itself is dispensable (Wun et al, 2008) , chemical substitutions at this position are detrimental for NKTcr recognition.
On the other hand, the recognition of the 4 0 a-GalCer analogues was quite varied. All Vb8.2 þ hybridomas recognised these aGalCer variants, but to different degrees, indicating that CDR3b sequences might influence this recognition ( Figure Figure 2B , middle row panel 4). Furthermore, the Vb7 þ NKT hybridoma recognised aGalCer and each of the 4 0 variants to similar extent, whereas the Vb6 þ hybridoma failed to respond to any of these lipid antigens ( Figure 2B , bottom row). These data suggest that the 4 0 -N-acetyl variant is a less potent antigen than the 4 0 -O-methyl and -O-ethanol analogues, thereby revealing an agonistic hierarchy in NKTcr ligands:
0 -N-acetyl analogue is not recognised by Vb14 þ hybridomas ( Figure 3B ), we conclude that the recognition of weak NKTcr ligands is influenced not only by CDR3b but also by CDR1b and CDR2b loops.
Vb usage also impacts iGb3 recognition
Low affinity of the CD1d-iGb3/NKTcr interaction has complicated structural, biochemical and functional studies of this ligand-receptor complex (Zhou et al, 2004; Zajonc et al, 2008) . We approached the structural analyses of this complex using a combination of iGb3 variants and the aforementioned hybridoma panel expressing Va14 a-chain paired with Vb8.2, Vb14, Vb7 or Vb6 b-chain. For this, 2 000 , 3 000 , 4 000 or 6 000 deoxy variants of the terminal galactose were incorporated into the phytosphingosine-based ceramide backbone during syntheses (Supplementary Figure S1C) .
As described above, we found that only Vb7 þ and Vb8.2 þ , with the exception of Vb8.2Jb2.2 þ , NKT hybridomas recognised iGb3 ( Figure 1A ), a pattern similar to 4 0 -Nacetyl-aGalCer recognition ( Figure 2B ). This recognition required the 2 000 -hydroxyl group within the terminal galactose by most (Vb8.2Jb2.5, Vb8.2Jb2.2, Vb8.2Jb2.4 and Vb8.2Jb2.2), and the 3 000 -hydroxyl by some (Vb8.2Jb2.5 and Vb8.2Jb2.2 only), Vb8.2 NKT hybridomas (Figure 3) . None of the Vb14 þ hybridomas recognised iGb3 or its deoxy variants (Figure 3) . Therefore, despite their obvious structural differences, the three CDRb loops impact iGb3 recognition in a manner similar to 4 0 -N-acetyl aGalCer recognition.
CDR1b and CDR3b residues, in addition to previously identified 'hotspots' influence the recognition of aGalCer variants The crystal structure of human CD1d-aGalCer/Va24-Vb11 NKTcr , as well as mouse CD1d-aGalCer/ Va14-Vb8.2 and CD1d-aGalCer/Va14-Vb7 NKTcrs , combined with mutagenesis studies (ScottBrowne et al, 2007; Wun et al, 2008; Mallevaey et al, 2009) , have shown that CDR1a, CDR3a and CDR2b residues are critical for CD1d-aGalCer recognition. As the 4 0 -aGalCer analogues were differentially recognised by different hybridomas (Figure 2 ), these variants were used in combination with a panel of Va14Ja18/Vb8.2Jb1.1-derived mutants with individual amino-acid alteration within their CDRs to determine the CDRb residues that influence recognition of the variant part of the antigen. The rationale behind this approach was that some of the Va14 NKTcr mutants may gain recognition and reveal the CDR residues that influence recognition either directly or indirectly. From the Va14-Vb8.2 NKTcr/CD1d-aGalCer crystal structure ), we were able to precisely gauge whether the effect of the alanine-scan mutants were likely a result of adverse affect on the conformation of the NKTcr (indirect effects, namely CDR1a: V26A, P28A, H31A, L32A, R33A; CDR1b: H27A, N29A and CDR2b: S47A, G49A) or on CD1d-antigen recognition (direct effects). Also note that none of the mutants become autoreactive to BMDCs, the APC used for antigen presentation (data not shown).
As reported previously Scott-Browne et al, 2007; Wun et al, 2008) , our results revealed that CDR1a, CDR3a and CDR2b residues were critical for aGalCer recognition (Figure 4 ). For the most part, residues critical for aGalCer recognition were also critical for 4 0 -O-methyl-and 4 0 -O-ethanol-aGalCer recognition (Figure 4) , suggesting that the footprint of the NKTcr binding to CD1d molecules remains essentially the same for these two variants. Exceptions were CDR1a mutants R33A, which did not recognise 4 0 -O-methyl or 4 0 -O-ethanol-aGalCer, and H31A, which did not recognise 4 0 -O-methyl-aGalCer, but partially recognised 4 0 -O-ethanolaGalCer (Figure 4) . The effects of H31A and R33A are perhaps indirect because they are thought to alter the fold of the NKTcr Scott-Browne et al, 2007; Wun et al, 2008; Pellicci et al, 2009) .
The 4 0 -N-acetyl variant was poorly (B20%) recognised by Va14Ja18/Vb8.2Jb1.1 TCR compared with recognition of aGalCer ( Figures 2B and 4) , but alteration of residues within CDR1a, CDR2a, CDR1b and CDR3b restored recognition of this variant (Figure 4) . Specifically, CDR1a mutants D29A and N30A, as well as CDR2a mutants V50A, D51A and D54A, overcame poor recognition of the 4 0 -N-acetyl variant (Figure 4) . Similarly, CDR1b mutants N26A and N29A and CDR3b mutant G94A also rescued defective recognition of the 4 0 -N-acetyl analogue (Figure 4) . Note that the differential recognition pattern of the mutant NKT hybridomas was not due to differences in TCR expression levels or activation thresholds because they were similar for all hybridomas as previously reported (Scott-Browne et al, 2007) . Together, these data suggest that the family of NKTcrs is afforded plasticity through different TCR b-chains, which, therefore, Figure S1B) overnight were co-cultivated with the same panel of NKT hybridomas described in Figure 1 . After 24 h, ELISA measured IL-2 secreted into the culture medium in response to NKT hybridoma activation. (B) BMDCs were pulsed with the indicated concentrations of aGalCer or its 4 0 -hydroxy variants and used to stimulate NKT hybridomas. Top row: Vb8.2Jb1.1 (circles); Vb8.2Jb2.1 (diamonds); Vb8.2Jb2.5 (triangles) and Vb8.2Jb2.6 (squares); middle row: Vb14Jb1.2i (circles); Vb14Jb1.2ii (diamonds); Vb14Jb2.5 (triangles) and Vb14Jb2.6 (squares); bottom row: Vb7 (diamonds) and Vb6 (squares). ELISA measured IL-2 secreted into the culture medium in response to NKT hybridoma activation. (C) Schematic rendition of NKTcr recognition pattern. Amino-acid sequence of CDR1b, CDR2b and CDR3b (upper case) of each Va14 TCR is indicated on the left; lowercase indicates residues flanking each CDR. Vb sequences were obtained from IMGT (http:// www.imgt.org/textes/IMGTrepertoire/). Data in panels A and B are representative of two independent experiments performed in triplicate.
aGalCer may be influenced by CDR residues outside these 'hotspots'. Consistent with this, the b-chain of the Vb7 þ and Vb6 þ NKTcrs was shown to have a greater role in interacting with CD1d-aGalCer in comparison with the Vb8.2 þ NKTcr Pellicci et al, 2009 ).
CDR2a, CDR1b and CDR3b residues impact on iGb3 recognition
The NKTcr mutant hybridomas were probed with iGb3 and its four deoxy analogues (Supplementary Figure S1C) , focusing on the 2 000 -and 3 000 -deoxy variants that were poorly recognised by the Va14Ja18/Vb8.2Jb1.1 NKTcrs ( Figure 5 ). In agreement with a previous study (Scott-Browne et al, 2007) , we also observed that iGb3 recognition involved the same germline-encoded 'hotspots', which include residues within CDR1a, CDR3a and CDR2b ( Figure 5 ). Furthermore, mutations within all three b-chain CDRs also affected recognition of iGb3, none of which, except CDR3b G94A, were rescued by the 2 000 -and 3 000 -deoxy variants ( Figure 5 ). Most interestingly, alanine mutations either partially (CDR2a V50A) or fully (CDR2a K53A and CDR3b G94A) rescued the recognition of 2 000 -deoxy-iGb3 and 3 000 -deoxy-iGb3, which were poorly recognised by the wt NKTcr ( Figure 5 ). From these data we conclude that iGb3 recognition by the NKTcr is distinct from aGalCer but shares some characteristics with that of 4 0 -Nacetyl-aGalCer. Furthermore, the data suggest a potential role of CDR1b and CDR3b, in addition to the CDR2a, loop in the recognition of iGb3.
CDR2a and CDR1b residues impact on aGalDAG recognition
Having determined that the aGalDAG recognition pattern by naturally occurring Va14 þ hybridomas was distinct from that of aGalCer and iGb3 (Figure 1) , we tested how the Va14 NKTcr mutants recognise this antigen. The responses of the mutant hybridomas again revealed that aGalDAG recognition involved the germline-encoded 'hotspots' within CDR1a, CDR3a and CDR2b (Figure 6 ). While none of the CDR3a mutants recognised aGalCer or iGb3, we found that CDR3a D93A uniquely recognised aGalDAG (Figures 4-6) . Further, although Y48A mutant does not recognise the three ligands, the remainder of CDR2b residues were differentially required for recognition: none were required for aGalCer, but S47, G51 and S52 were required for iGb3 while S47 and S52 were required for aGalDAG recognition (Figures 4-6) . A similar discordance was also observed with CDR3b mutants: none were critical for aGalCer and aGalDAG recognition (Figures 4  and 6 ), but many (S93, T95, T96 and T98) were critical for Figure 3 NKTcr interfaces CD1d-iGb3 with a distinct recognition logic. (A) BMDCs pulsed with 10 mg/ml iGb3, 2 000 -deoxy-iGb3, 3 000 -deoxyiGb3, 4 000 -deoxy-iGb3 or 6 000 -deoxy-iGb3 were used to stimulate a panel of NKT hybridomas described in Figure 1 . After 24 h, ELISA measured IL-2 secreted into the culture medium in response to NKT hybridoma activation. Data are representative of two independent experiments performed in triplicate. (B) Schematic rendition of NKTcr recognition pattern. Amino-acid sequence of CDR1b, CDR2b and CDR3b (upper case) of each Va14 TCR is indicated on the left; lowercase indicates residues flanking each CDR (for sequences see http://www.imgt.org/textes/ IMGTrepertoire/). iGb3 recognition ( Figure 5 ). Moreover, CDR2a residues V50 and K53, which were required for 2 000 -deoxy iGb3 recognition, along with D54, were critical for aGalDAG recognition, but were irrelevant for aGalCer recognition (Figures 4-6 ). These data indicate that the galactose head group of aGalDAG when bound to CD1d is disposed differently from the galactose of aGalCer. Thus, while maintaining a common NKTcr footprint mediated by the 'hotspots', effective recognition of aGalDAG involves different contact residues within these hotspots, and additionally requires CDR2a and CDR1b residues.
Discussion
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-20% Figure 4 The 4 0 -N-acetyl aGalCer variant interacts with Va14 TCR with a unique register. (A) BMDCs pulsed with 500 ng/ml aGalCer, 4 0 -Omethyl, 4 0 -O-ethanol or 4 0 -N-acetyl variants were used to stimulate a panel of NKTcr mutants consisting of a single point mutation within CDR1, CDR2 and CDR3 of both TCR a-and b-chains. The Va3.2 þ NKT hybridoma was used as the negative control. After 24 h, ELISA measured IL-2 secreted into the culture medium in response to NKT hybridoma activation. As the wt hybridoma and the derived mutants were equally sensitive to antigen-independent stimulation (Scott-Browne et al, 2007) , the data were normalised to wt IL-2 response to aGalCer-pulsed BMDCs and represented as mean ± s.e.m. of three independent experiments performed in triplicate. (B) Schematic rendition of NKTcr recognition pattern.
et al, 2009). Collectively, these structures have revealed a similar docking mode between the Va14-Vb8.2, Va14-Vb7 and Va24-Vb11 NKTcrs. These structures also revealed that differences in Vb-chain usage nevertheless impacted on CD1d-aGalCer recognition. How differing Vb usage would impact on recognising CD1d-restricted antigens other than aGalCer was less clear. In the absence of the crystal structures of NKTcr/CD1d-iGb3 and NKTcr/CD1d-aGalDAG, we have used an approach based on functional recognition to delineate how semi-invariant NKTcrs recognise diverse ligands. The approach involved probing a panel of naturally occurring Va14 TCRs and derived point mutants that have altered CDRs with a panel of CD1d-restricted glycolipids and their sugar variants. Importantly, the recently solved crystal structure of the Va14-Vb8.2 NKTcr/CD1d-aGalCer structure enabled us to ascertain the mutations that are likely to exert indirect effects (e.g., CDR1a: V26A, P28A, H31A, L32A, R33A; CDR1b: H27A, N29A; CDR2b: S47A; G49A ) versus mutations that would impact directly on recognition.
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Our results revealed several hitherto unknown key features of diverse ligand recognition by NKTcr: first, we found that distinct epitopic sites in aGalCer and iGb3 were critical for recognition. Second, recognition of weak CD1d-restricted NKTcr agonists critically depended on the b-chain that paired with the Va14 a-chain. Third, we discovered that while the NKTcrs dock on CD1d with a conserved footprint, they are malleable enough to recognise aGalDAG, which is structurally related to aGalCer, and the structurally most divergent iGb3 ( Figure 7B ). Fourth, as we will discuss below, our data best fit the 'squash' model for iGb3 recognition by the NKTcr ( Figure 7A) .
We found that the Va14 NKTcr is intolerant to chemical modifications at the 3 0 position of aGalCer even though the 3 0 -hydroxyl is dispensable for NKTcr recognition (Wun et al, 2008) . On the other hand, the Va14 NKTcr was tolerant to multiple 4 0 modifications, consistent with the previous finding that the 4 0 -hydroxyl is dispensable for recognition (Wun et al, 2008) . Nonetheless, a unique modification of aGalCer with 4 0 -N-acetyl was very poorly recognised by Va14Ja18-Vb8.2Jb1.1 TCR. Its recognition was rescued by several mutations within CDR1a, CDR2a, CDR1b and CDR3b, many of which are surprisingly outside the common binding footprint. Thus, the CDRb loops appear to complement the recognition landscape formed by the a-chain CDRs.
The 2 000 -and 3 000 -hydroxyls of the terminal a1,3Gal of iGb3 were essential for Va14Ja18-Vb8.2Jb1.1 recognition. As with the 4 0 -N-acetyl-aGalCer variant, mutations within CDR1a, CDR2a and CDR3b rescued recognition of both the deoxyiGb3 variants. Because this and previous mutagenesis studies revealed germline-encoded CDR1a, CDR3a and CDR2b 'hotspots' in aGalCer and iGb3 recognition (Scott-Browne et al, 2007), we assume that the Va14 NKTcr docks on both CD1d-aGalCer and CD1d-iGb3 complexes in a similar mode. The perpendicular disposition of the trihexoses of iGb3 in an unliganded state (Zajonc et al, 2008) as compared with the parallel orientation of the monohexose in CD1d-aGalCer (Zajonc et al, 2005) structure poses a serious recognition problem, and would result in steric clashes with the NKTcr (Figure 7A ) if one assumed a docking mode similar with respect to CD1d-aGalCer recognition. Thus, we suggest that the glycan moiety of iGb3 is flattened upon NKTcr engagement, which is analogous to the TCR-induced flattening of extremely bulged pMHC class-I ligands (Tynan et al, 2007) . However, with our current data, it is not possible to speculate on precisely how iGb3 might be flattened to fit into an NKTcr/ CD1d-antigen complex. Notwithstanding, because LacCer and Gb3, which are related to iGb3, are not recognised by the NKTcr (Zhou et al, 2004) , it appears as though the terminal a1-3Gal in iGb3, in its squashed position, provides critical new contact(s) that are required for binding to CD1d, NKTcr or both.
CD1d-aGalDAG recognition by the Va14 NKTcr also involves the previously reported germline-encoded 'hotspots' made up of residues within CDR1a, CDR3a and CDR2b. In addition, it involves additional unique residues contributed by other CDR many of which are dispensable for aGalCer and iGb3 recognition. Most importantly, CDR2a V50, K53 and D54 were critical for aGalDAG recognition. These results suggest that the positioning of the galactosyl group in aGalDAG differs from that of aGalCer. In the recently reported model, the diacylglycerol backbone of aGalDAG is predicted not to form the critical hydrogen bond network with CD1d R79 and D80. Hence, it is expected that the galactose in aGalDAG is raised above the plane of the galactose in aGalCer and is moved away from the a2-helix (Kinjo et al, 2006) . A similar disposition of the galactose is observed when human CD1d displays aGalCer that is caused by a species variation (human W153, which is equivalent to mouse G155; Koch et al, 2005; Zajonc et al, 2005) . The putative differences in the disposition between the galactoses of aGalDAG and aGalCer when displayed by CD1d might explain the distinct logic used by the NKTcr for aGalDAG and aGalCer recognition.
We found that the b-chain played a significant role in 4 0 -Nacetyl-aGalCer, iGb3, iGb3 analogues and aGalDAG recognition because none of the Vb14 þ NKTcr recognised these ligands. This could partly be because Vb14 lacks the CDR2b Y48 residue, which is critically important for the binding of Vb8.2-containing NKTcr to CD1d ScottBrowne et al, 2007; Wun et al, 2008; Mallevaey et al, 2009) . Equally intriguing was the finding that despite the lack of Y48, Vb14 þ NKTcr recognised aGalCer. This is perhaps because Y46 present in Vb14 compensates for the absence of Y48. Notwithstanding, Vb14 þ NKTcr did not recognise iGb3 or aGalDAG. As well as because CDR2b Y46-containing Vb6 þ NKTcr does not recognise any of the ligands tested, we predict that CDR3b contributes significantly to the energetic landscape for low-affinity ligand recognition (4 0 N-acetylaGalCer, aGalDAG and iGb3), perhaps by influencing the structure of the closely disposed CDRa loops. A recent report identified an I/LxxPI/L (I, L and P are isoleucine, leucine and proline; x is any amino acid) motif within CDR3b as a potential contributor for Vb6 þ NKTcr antigen recognition V26A  P28A  D29A  N30A  H31A  L32A  R33A  V50A  D51A  Q52A  K53A  D54A  D93A  R94A  G95A  S96A  L98A   T24A  N25A  N26A  H27A  N28A  N29A  S47A  Y48A  G49A  G51A  S52A  G92A  S93A  G94A  T95A  T96A  N97A  T98A   300 The aGalDAG recognition logic is distinct from that of aGalCer or iGb3 recognition by NKTcr. BMDCs pulsed with 20 mg/ml aGalDAG were used to stimulate a panel of NKTcr mutants and activation was measured as described in Figure 4A . Data were normalised as described in Figure 4A and represent the mean ± s.e.m. of at least three independent experiments performed in triplicate.
explain the exclusion of the majority of the b-chains from the NKTcr repertoire during positive selection , which is presumably mediated by low-affinity selfligands. Thus, we conclude that the b-chain CDRs fine-tune the affinity threshold for NKTcr ligand recognition. While CDR3b did not appear to play a key role in recognition of aGalCer, variations in its length and composition did impact on the recognition of analogues of aGalCer and iGb3, as well as aGalDAG. Existing structural data Pellicci et al, 2009) have not supported a key role for CDR3b in direct recognition of CD1d-aGalCer; however, some CDR3b conformations appear to be more permissive than others for CD1d-glycolipid-antigen recognition ( Taken together, the impact of CDR3b conformation seems to vary as a function of the glycolipid antigen. It is difficult to speculate on precisely how CDR3b is contributing to recognition in these instances, although some CDR3b conformations might inhibit binding through steric hindrance, as suggested for the human NKT-15 TCR (Kjer-Nielsen et al, 2006) , and some may indirectly affect recognition by altering the juxtaposition of other CDR regions that are involved in direct binding as has been observed in the structure of Va14-Vb7 NKTcr/CD1d-aGalCer complex in comparison to that of Va14-Vb8.2 NKTcr/CD1d-aGalCer complex .
In sum, the second site-suppression strategy allowed us to gain new insight into how the NKTcr recognises multiple 000 -deoxy analogue of iGb3 (right). TCR surface (pale cyan); CDR1a (orange); CDR2a (green); CDR3a (blue); CDR1b (pale green); CDR2b (pink) and CD1d helices (dark grey); CDR3b is not shown.
ligands, especially of CD1d-iGb3 and CD1d-aGalDAG complexes for which crystal structures of the receptor/antigen co-complexes are yet to be solved. Our data reinforce the previously reported common docking footprint, but extend the recognition logic significantly further for the recognition of weak/low-affinity agonists. Such weak agonists require other areas of the recognition landscape (e.g., CDR2a, CDR1b and CDR3b) to achieve the energy necessary for NKT-cell activation. Therefore, we conclude that there is a consistent logic with which the NKTcr positions its 'hotspot' to find the epitope. The malleable nature of NKTcrs described herein then determines whether the orientation with which they 'perch' on the antigens, especially weak agonists, can be stabilised sufficiently to generate an activation signal. These new insights can be used to design altered glycolipid ligands that will have the potential to steer downstream immune responses in a desired manner.
Materials and methods
Mice C57BL/6 mice were purchased from the Jackson Laboratory and used in compliance with Vanderbilt Institutional Animal Care and Use Committee-approved regulations.
Glycolipids
The syntheses and structure validation of all aGalCer and iGb3 and their variants are described elsewhere (Chen et al, 2007; Xia et al, 2009) . aGalCer and iGb3 and their sugar variants were dissolved in DMSO at 1 mg/ml and used at the indicated concentrations. aGalDAG preparation and use has been reported (Kinjo et al, 2006) .
Preparation of BMDC
BM cells were harvested from the femurs of 8 to 10-week-old C57BL/6 mice and differentiated into DC by cultivating precursors in petridishes for 7 days in RPMI þ (RPMI-1640 supplemented with 10% fetal calf serum (FCS), 1% L-glutamine, 1 mM penicillin/ streptomycin; CellGrow) containing 20 ng/ml recombinant murine colony-stimulating factor-2 (rCsf-2; PeproTech). On days 3 and 5 of culture, 70% of the medium containing non-adherent cells was removed and replaced with fresh medium containing 20 ng/ml of rCsf-2. On day 7, the loosely adherent and non-adherent cells largely containing BMDCs and some granulocytes were harvested and used immediately for antigen loading.
NKT hybridoma stimulation and ELISA All Va14 þ mouse NKT hybridomas N38-3C3, DN32.D3, N37-1H5a, N38-2C12, N57-2C12, N57-2B6, H41-2C9, H41-3C5, H41-2D9, N38-2H4, Va14-DOb and its alanine mutants have been described (Lantz and Bendelac, 1994; Gui et al, 2001; Scott-Browne et al, 2007) . TCR a-and b-chain usage and CDR sequences are shown in Supplementary Table S1 . They were maintained in RPMI þ containing 55 mM 2-mercaptoethanol. BMDCs were dispensed into roundbottomed microtitre plates at a density of 3 Â10 4 cells/well and incubated with increasing concentrations of aGalCer and its 3 0 and 4 0 variants, (0.1-500 ng/ml), iGb3 and its deoxy variants (10 mg/ml) or aGalDAG (20 mg/ml) for 18-24 h at 371C. Lipid-loaded BMDCs were washed twice with warm PBS and co-cultivated with 6 Â10 4 NKT hybridoma cells per well for 24 h at 371C. Cell-free supernatant was harvested and IL-2 secreted during co-culture was determined by ELISA.
TCR modelling
The NKTcr/CD1d-iGb3 model was prepared based on the previously reported crystal structure of CD1d-iGb3 complex (Zajonc et al, 2008) and the Va14Vb8.2 crystal structure . All NKTcr-CD1d models were prepared in an identical docking orientation as observed in the Va14Vb8.2/CD1d-aGalCer crystal structure .
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
